ST. LOUIS--(BUSINESS WIRE)--Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, presented key research findings that showcased the capabilities of its stool-based RNA platform at the Digestive Disease Week (DDW) 2024 meeting. Results showed that Geneoscopy’s novel RNA technology can assess therapeutic response for patients with inflammatory bowel disease (IBD) and transform colorectal cancer (CRC) screening, potentially impacting millions of patients in need. Geneoscopy also participated in three invite-only panel presentations hosted by Colorectal Cancer Alliance, Fight CRC, and Johnson & Johnson.
“Participating and presenting at DDW offered an incredible opportunity to highlight the potential of Geneoscopy’s noninvasive RNA technology in transforming gastrointestinal health,” said Dr. Erica Barnell, Chief Science and Medical Officer at Geneoscopy. “Our company is at the leading edge of a new frontier where healthcare providers are empowered with actionable insights from innovative tests that help prevent, detect, and monitor disease, ultimately improving patient outcomes.”
A poster, titled Stool-derived eukaryotic RNA assay approximates disease activity index and predicts therapeutic response in patients with Crohn’s disease on advanced therapies, found that the RNA signatures showed high accuracy in distinguishing subjects with active disease from those in remission with further subcategorization of active inflammation based on disease severity. This method demonstrated consistent detection of RNA biomarkers in stool samples and effective prediction of therapeutic response across different targeted therapies.
A second poster presentation, titled Development of a second-generation multi-target stool RNA test (ColoSense 2.0) for colorectal cancer screening, demonstrated a preliminary ability to leverage bio-banked stool samples to improve the accuracy of Geneoscopy’s RNA-based ColoSense test, which recently received FDA approval for CRC screening of average-risk individuals over the age of 45. Novel stool-based RNA biomarkers improved sensitivity for detecting CRC and advanced adenomas while maintaining high specificity for no lesions on colonoscopy. Ongoing efforts aim to enhance the ColoSense performance by identifying novel biomarkers to further refine its diagnostic accuracy utilizing next-generation sequencing technology.
“In addition to presenting these impactful study results at the DDW meeting in Washington D.C., our team engaged with advocacy partners, policymakers, professional societies, and legislative bodies to address the pressing issues in gastrointestinal health,” said Matt Sargent, Chief Commercial Officer at Geneoscopy. “As the number of Americans suffering from gastrointestinal diseases increases, it’s crucial that we come together and take the needed steps to educate and offer both physicians and their patients better, more convenient, and personalized treatment options.”
Studies have shown that approximately 30% of IBD patients do not respond to initial treatment, highlighting a critical need for tools to inform therapy selection. Additionally, compliance rates for preventative measures like CRC screening remain low. More than 44 million Americans at average risk for CRC remain unscreened despite screening's vital role in early detection and prevention. Geneoscopy’s technology provides reliable, scalable, and cost-effective evaluation of RNA biomarkers from stool samples, delivering the ideal platform for developing diagnostic tests for gastrointestinal health.
About DDW
Digestive Disease Week® (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA), the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW is an annual in-person and online meeting. This year’s meeting was held from May 18-21, 2024 in Washington, D.C. and showcased more than 4,400 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. More information can be found at www.ddw.org.
About Geneoscopy, Inc.
Geneoscopy Inc. is a life sciences company focused on developing diagnostic tests for gastrointestinal health. Leveraging its proprietary, patented stool-derived eukaryotic RNA (seRNA) biomarker platform, Geneoscopy’s mission is to empower patients and providers to transform gastrointestinal health through innovative diagnostics. The company’s FDA-approved ColoSense™ test uses a proprietary RNA-based platform to screen for colorectal cancer and advanced adenomas for average-risk individuals over the age of 45. In partnership with leading universities and biopharmaceutical companies, Geneoscopy is also developing diagnostic tests for treatment selection and therapy monitoring in other GI disease areas. For more information, visit www.geneoscopy.com and follow the company on LinkedIn.
